Immunovaccine, Inc. has signed a collaborative research agreement with Vaxil BioTherapeutics to explore the efficacy of Vaxil’s cancer antigens in Immunovaccine’s DepoVax vaccine enhancement platform. “Vaxil has an innovative approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long peptides are good candidates for formulation in our DepoVax platform making this an interesting research partnership,” said Dr. M...